Sentia Medical Sciences
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3550 General Atomics Ct Bldg 2564, San D...Phone Number
(858) 886-7709Website
www.sentiamedical.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Sentia Medical Sciences
Sentia Medical Sciences, Inc. is focused on developing novel peptide therapeutics aimed at managing and curing stress-related diseases. The company specializes in creating drugs known as astressins, which block the action of corticotropin releasing factor and urocortins, key mediators of the body's stress response. Their therapeutic solutions target various conditions, including Irritable Bowel Syndrome, Postoperative Ileus, and Gastroparesis. Sentia aims to lead the market in providing effective treatments that restore biological harmony and alleviate the impact of stress on health.Explore more
Sentia Medical Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sentia Medical Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Sentia Medical Sciences is spiking on competitors!
Product Launch: Get notified when Sentia Medical Sciences launches new products
Sentia Medical Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Sentia Medical Sciences had a recent Job posting/layoffs
Check if Sentia Medical Sciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Sentia Medical Sciences
Earning: See what the market has to say on Sentia Medical Sciences recently announced quarterly report
Funding: Get notified immidiatlly once Sentia Medical Sciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Sentia Medical Sciences as Masked Content
Find more new buyers
Compare Similar Companies to Sentia Medical Sciences
Compare insights from companies similar to Sentia Medical Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sentia Medical Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sentia Medical Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sentia Medical Sciences.
Sentia Medical Sciences Tech Stack
A closer look at the technologies used by Sentia Medical Sciences
Sentia Medical Sciences News & Media
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with thSentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
SAN DIEGO, May 22, 2019 (GLOBE NEWSWIRE) -- Sentia announced today that it has been awarded a phase II small business innovation research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of approximately $1.8 million to support the development of astressins for the treatment of IBS. Astressins are potent and long-acting peptide antagonists of corticotropin releasing factor (CRF) receptors 1 and 2.Sentia Medical Sciences Inc. Appoints Dr. Yvette Taché as Chair of the Scientific Advisory Board and Announces Award of a Phase 1 Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Sentia announced today the appointment of Dr. Yvette Taché, Ph.D. as Chair of the Scientific Advisory Board. Dr. Taché, Ph.D. is a Distinguished Professor in the Vatche and Tamar Manoukian Digestive Diseases Division, David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Senior Research Career Scientist at the Veterans Affairs Medical Center, Los Angeles. Yvette is a world-renowned figure in the fieldSentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases
SAN DIEGO, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Sentia announced today that it will bring to fruition several decades of academic research by developing a new generation of first in class drug candidates called astressins. Astressins are peptide antagonists that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the body’s response to stress. CRF and urocortins are the factors that initiate and direct the stress response, and are crucial
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sentia Medical Sciences
Sign Up For FreeTo access detailed company insights
Sentia Medical Sciences, Inc. is focused on developing novel peptide therapeutics aimed at managing and curing stress-related diseases. The company specializes in creating drugs known as astressins, which block the action of corticotropin releasing factor and urocortins, key mediators of the body's stress response. Their therapeutic solutions targe... Read More
